Date of Abstract presentation12th December 2023IndicationsAcute LeukemiaAbstract NumberLBA-5Abstract typePoster
According to the data presented at the ASH 2023 conference, as of the July 2023 data cutoff, the pivotal trial AUGMENT-101 included 94 patients with acute leukemia within the KMT2Ar cohorts. Among them, 57 individuals received central confirmation of their KMT2Ar status, had adequate follow-up, and were part of the population evaluated for efficacy. Among the patients evaluated for efficacy, a notable 63% demonstrated an overall response, while 44% achieved a composite response (CRc). Minimal residual disease (MRD) status was examined in 22 out of the 25...
